PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10345505

Platelet function testing by flow cytometry.

H M Rinder
View original source ↗Export metadata ↓

Abstract

The availability of fluorescent monoclonal antibodies and probes now provides a powerful tool for examining platelet function by flow cytometry. These techniques cna be employed to determine the resting and stimulated expression of platelet glycoprotein receptors, the activation status of platelets assessed by secretion of granule contents (including expression of activation-dependent neoantigens), adhesion ligand binding to platelets, and intracellular calcium flux after exposure of platelets to agonist. In addition, flow cytometry has now been used to study the functional properties of stimulated platelets, including microparticle generation, platelet aggregation, and platelet-heterotypic cell conjugate formation. This brief review is presented as a general outline of the literature that uses flow cytometric methodology to examine in vivo and ex vivo platelet function.

Explore related subjects

Blood Platelet DisordersBlood PlateletsCell DegranulationFlow CytometryFluorescent DyesHumansInfant, NewbornPlatelet AggregationPlatelet Function TestsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H M Rinder. Platelet function testing by flow cytometry.. https://pubmed.ncbi.nlm.nih.gov/10345505/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.

The Quebec platelet disorder (QPD) is an autosomal dominant platelet disorder associated with delayed bleeding and alpha-granule protein degradation. The degradation of alpha-granule, but not plasma, fibrinogen in patients with the QPD led to the investigation of their platelets for a protease defect. Unlike normal platelets, QPD platelets contained large amounts of fibrinolytic serine proteases that had properties of plasminogen activators. Western blot analysis, zymography, and immunodepletion experiments indicated this was because QPD platelets contained large amounts of urokinase-type plasminogen activator (u-PA) within a secretory compartment. u-PA antigen was not increased in all QPD plasmas, whereas it was increased more than 100-fold in QPD platelets (P <.00009), which contained increased u-PA messenger RNA. Although QPD platelets contained 2-fold more plasminogen activator inhibitor 1 (PAI-1) (P <.0008) and 100-fold greater u-PA-PAI-1 complexes (P <.0002) than normal platelets, they contained excess u-PA activity, predominantly in the form of two chain (tcu-PA), which required additional PAI-1 for full inhibition. There was associated proteolysis of plasminogen in QPD platelets, to forms that comigrated with plasmin. When similar amounts of tcu-PA were incubated with normal platelet secretory proteins, many alpha-granule proteins were proteolyzed to forms that resembled degraded QPD platelet proteins. These data implicate u-PA in the pathogenesis of alpha-granule protein degradation in the QPD. Although patients with the QPD have normal to increased u-PA levels in their plasma, without evidence of systemic fibrinogenolysis, their increased platelet u-PA could contribute to bleeding by accelerating fibrinolysis within the hemostatic plug. QPD is the only inherited bleeding disorder in humans known to be associated with increased u-PA.

Blood Platelet Disorders↗
PubMed2001

Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.

The PFA-100 (platelet function analyser) is a relatively new tool for the investigation of primary haemostasis. Recent studies have shown its utility in monitoring antiplatelet therapy (including aspirin) and as a screening tool for investigating possible von Willebrand disease (vWD) and various platelet disorders. More recently, the PFA-100 has been shown to be of value in monitoring DDAVP therapy in both vWD and platelet disorders. This paper reviews current findings, details the utility of the PFA-100 for some of these purposes, as well as reviewing analytical variables that may complicate the interpretation of results. The author highlights the benefits, as well as noting the limitations, of its use. Ultimately, the greatest strengths of the PFA-100 are its simplicity in use and excellent sensitivity to particular haemostatic disturbances such as vWD, platelet disorders and platelet-affecting medication. However, because it is thus a 'global' test system, this also creates a significant limitation, as the PFA-100 is not specific for, nor predictive of, any particular disorder. However, utilized appropriately, the PFA-100 can be considered a worthwhile addition to any haemostasis laboratory involved in the diagnosis or therapeutic-monitoring of bleeding disorders including vWD and platelet-dysfunctions. This review should be of value to both haemostasis scientists and clinical specialists.

Blood Platelet Disorders↗